See more : Moog Inc. (MOG-B) Income Statement Analysis – Financial Results
Complete financial analysis of Veru Inc. (VERU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Veru Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bright Lights Acquisition Corp. (BLTSW) Income Statement Analysis – Financial Results
- Angkor Resources Corp. (ANK.V) Income Statement Analysis – Financial Results
- Lululemon Athletica Inc. (LULU) Income Statement Analysis – Financial Results
- Quaterra Resources Inc. (QTRRF) Income Statement Analysis – Financial Results
- Quantum eMotion Corp. (QNCCF) Income Statement Analysis – Financial Results
Veru Inc. (VERU)
About Veru Inc.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.89M | 16.30M | 39.35M | 61.26M | 42.59M | 31.80M | 15.86M | 13.66M | 22.13M | 32.60M | 24.49M | 31.46M | 35.03M | 18.57M | 22.22M | 27.54M | 25.63M | 19.32M | 14.82M | 11.16M | 8.83M | 9.05M | 8.42M | 6.72M | 5.77M | 4.72M | 5.45M | 2.92M | 2.06M | 2.20M | 16.20M | 12.50M | 11.20M | 13.10M | 10.70M |
| Cost of Revenue | 11.03M | 8.73M | 8.76M | 13.33M | 11.81M | 10.15M | 7.08M | 6.64M | 8.78M | 13.63M | 11.37M | 13.95M | 14.41M | 8.70M | 9.30M | 14.03M | 14.90M | 12.16M | 9.33M | 6.37M | 5.21M | 5.46M | 4.86M | 5.34M | 3.60M | 3.31M | 5.27M | 3.48M | 3.68M | 2.50M | 7.50M | 6.90M | 6.10M | 7.20M | 6.10M |
| Gross Profit | 5.85M | 7.57M | 30.59M | 47.93M | 30.79M | 21.66M | 8.78M | 7.02M | 13.35M | 18.97M | 13.12M | 17.50M | 20.62M | 9.87M | 12.92M | 13.52M | 10.73M | 7.16M | 5.49M | 4.79M | 3.62M | 3.59M | 3.56M | 1.38M | 2.16M | 1.40M | 178.03K | -559.30K | -1.62M | -300.00K | 8.70M | 5.60M | 5.10M | 5.90M | 4.60M |
| Gross Profit Ratio | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.10% | 55.36% | 51.40% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53.14% | 58.16% | 49.08% | 41.86% | 37.04% | 37.03% | 42.93% | 41.03% | 39.67% | 42.31% | 20.52% | 37.49% | 29.70% | 3.27% | -19.18% | -78.50% | -13.64% | 53.70% | 44.80% | 45.54% | 45.04% | 42.99% |
| Research & Development | 12.81M | 51.20M | 70.65M | 32.69M | 16.94M | 13.74M | 10.85M | 3.50M | 99.39K | 219.82K | 5.58K | 4.75K | 5.28K | 10.93K | 381.00 | 105.92K | 284.22K | 208.61K | 210.88K | 273.78K | 179.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 361.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.02M | 8.66M | 12.13M | 9.14M | 7.49M | 9.63M | 6.23M | 6.43M | 7.01M | 7.04M | 5.89M | 4.82M | 5.71M | 4.46M | 4.89M | 4.93M | 1.85M | 2.97M | 3.14M | 2.90M | 3.04M | 2.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.27K | 88.87K | 0.00 | 58.12K | 221.72K | 52.95K | 332.76K | 220.18K | 191.15K | 223.80K | 179.87K | 218.50K | 123.10K | 47.60K | 36.53K | 43.83K | 129.16K | 0.00 | 0.00 | 433.82K | 1.64M | 2.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.07M | 8.75M | 12.13M | 9.20M | 7.71M | 9.68M | 6.56M | 6.65M | 7.20M | 7.26M | 6.07M | 5.04M | 5.83M | 4.51M | 4.92M | 4.97M | 1.98M | 2.97M | 3.14M | 3.33M | 4.68M | 5.97M | 8.00M | 10.70M | 8.10M | 6.20M | 7.10M | 3.70M |
| Other Expenses | -1.22M | 2.09M | -316.06K | -8.71M | 14.10M | -5.89M | -2.20M | 15.51M | 9.20M | 9.20M | 9.20M | 7.71M | 2.01M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 1.83M | 1.28M | 0.00 | 0.00 | 0.00 | 100.00K | 500.00K | 400.00K | 300.00K | 200.00K | 100.00K |
| Operating Expenses | 42.77M | 101.35M | 113.81M | 53.36M | 45.53M | 28.09M | 29.65M | 14.58M | 10.33M | 12.35M | 9.20M | 7.71M | 9.68M | 6.57M | 6.65M | 7.30M | 7.55M | 6.28M | 5.25M | 6.10M | 4.69M | 4.92M | 6.23M | 1.98M | 4.80M | 4.43M | 3.33M | 4.68M | 6.33M | 8.10M | 11.20M | 8.50M | 6.50M | 7.30M | 3.80M |
| Cost & Expenses | 53.80M | 110.08M | 122.58M | 66.70M | 57.34M | 38.24M | 36.74M | 21.21M | 19.11M | 25.99M | 20.57M | 21.67M | 24.09M | 15.27M | 15.94M | 21.33M | 22.45M | 18.44M | 14.58M | 12.47M | 9.90M | 10.38M | 11.09M | 7.32M | 8.41M | 7.74M | 8.60M | 8.15M | 10.01M | 10.60M | 18.70M | 15.40M | 12.60M | 14.50M | 9.90M |
| Interest Income | 0.00 | 0.00 | 4.37M | 4.89M | 4.62M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.17K | 55.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 607.47K | 2.43M | 4.37M | 4.85M | 4.62M | 4.71M | 2.95M | 2.04M | 3.32M | 0.00 | 50.57K | 0.00 | 296.18K | 124.63K | 3.98M | 2.39M | 0.00 | 74.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 268.18K | 269.87K | 209.60K | 593.87K | 783.64K | 471.42K | 452.05K | 481.01K | 422.87K | 494.26K | 589.34K | 556.30K | 461.45K | 464.91K | 466.54K | 268.38K | 217.09K | 252.94K | 333.63K | 522.80K | 1.09M | 1.55M | 1.01M | 923.92K | 1.83M | 1.28M | 533.99K | 553.30K | 675.08K | -100.00K | -500.00K | -400.00K | -300.00K | -200.00K | -100.00K |
| EBITDA | -36.20M | -89.98M | -79.23M | 9.75M | -14.65M | -7.14M | -19.67M | -8.12M | 4.92M | 7.11M | 4.51M | 10.35M | 11.40M | 3.76M | 4.69M | 5.32M | 3.40M | 1.01M | 573.99K | -1.11M | 19.17K | 210.53K | -1.66M | 321.06K | -812.89K | -1.74M | -2.73M | -4.76M | -7.10M | -8.30M | -2.20M | -2.50M | -1.10M | -1.60M | 800.00K |
| EBITDA Ratio | -214.38% | -552.10% | -211.47% | -38.93% | -34.62% | -20.24% | -131.57% | -44.52% | 16.22% | 21.64% | 18.77% | 33.21% | 31.65% | 18.08% | 39.04% | 26.99% | 9.08% | 6.19% | 3.96% | -6.94% | 0.94% | 2.33% | -4.75% | 2.98% | -16.61% | -39.07% | -50.15% | -163.37% | -340.18% | -377.27% | -13.58% | -20.00% | 8.93% | -12.21% | 7.48% |
| Operating Income | -36.92M | -93.78M | -83.22M | -5.44M | -14.75M | -6.44M | -20.87M | -8.49M | 3.02M | 6.62M | 3.92M | 9.79M | 10.94M | 3.30M | 4.35M | 4.72M | 3.18M | 875.91K | 240.36K | -1.31M | -1.07M | -1.34M | -2.67M | -602.86K | -2.64M | -3.03M | -3.15M | -5.24M | -7.95M | -8.20M | -1.70M | -2.10M | 1.30M | -1.40M | 900.00K |
| Operating Income Ratio | -218.61% | -575.46% | -211.47% | -8.88% | -34.62% | -20.24% | -131.57% | -62.20% | 13.64% | 20.30% | 16.02% | 31.12% | 31.23% | 17.75% | 19.57% | 17.13% | 12.42% | 4.53% | 1.62% | -11.75% | -12.09% | -14.76% | -31.72% | -8.98% | -45.75% | -64.17% | -57.80% | -179.62% | -385.12% | -372.73% | -10.49% | -16.80% | 11.61% | -10.69% | 8.41% |
| Total Other Income/Expenses | -160.93K | 1.11M | -316.06K | -8.71M | -5.31M | -5.89M | -2.20M | -108.38K | -204.60K | 68.63K | 33.28K | 144.26K | -147.91K | -63.37K | -125.03K | 332.10K | 1.02M | -7.00K | -12.35K | -44.40K | 0.00 | 0.00 | -1.26M | -568.40K | 145.20K | 100.18K | 117.14K | 79.53K | -252.61K | 0.00 | 1.00M | 0.00 | 600.00K | 400.00K | 200.00K |
| Income Before Tax | -37.08M | -92.67M | -83.54M | 4.27M | -20.05M | -12.32M | -23.07M | -8.60M | 2.81M | 6.69M | 3.96M | 9.93M | 10.79M | 3.23M | 4.22M | 5.05M | 4.20M | 868.91K | 228.01K | -1.33M | -1.07M | 0.00 | -3.93M | -1.17M | -2.49M | -2.93M | -3.03M | -5.16M | -8.20M | 0.00 | -1.50M | 0.00 | -800.00K | -1.00M | 1.00M |
| Income Before Tax Ratio | -219.56% | -568.65% | -212.28% | 6.96% | -47.08% | -38.74% | -145.43% | -63.00% | 12.72% | 20.51% | 16.16% | 31.58% | 30.80% | 17.41% | 19.01% | 18.34% | 16.40% | 4.50% | 1.54% | -11.87% | -12.09% | 0.00% | -46.67% | -17.44% | -43.23% | -62.05% | -55.65% | -176.89% | -397.36% | 0.00% | -9.26% | 0.00% | -7.14% | -7.63% | 9.35% |
| Income Tax Expense | 725.10K | 480.21K | 236.40K | -3.13M | -1.08M | -303.93K | 866.10K | -1.99M | 2.47M | 2.34M | 1.52M | -4.41M | -4.51M | -2.17M | -2.51M | -1.49M | -762.86K | -825.00K | -29.32K | 58.51K | 1.02M | 1.04M | 2.07M | 447.43K | 906.65K | 624.13K | 89.28K | 291.21K | 963.00K | 100.00K | 1.30M | 1.60M | 5.60M | 100.00K | 600.00K |
| Net Income | -37.80M | -93.15M | -83.78M | 7.39M | -18.97M | -12.02M | -23.94M | -6.61M | 344.73K | 4.35M | 2.43M | 14.34M | 15.30M | 5.40M | 6.74M | 6.54M | 4.97M | 1.69M | 282.03K | -1.36M | -2.02M | -2.37M | -3.48M | -1.17M | -3.69M | -3.75M | -3.36M | -5.61M | -8.66M | -8.30M | -3.00M | -3.70M | -4.30M | -1.50M | 300.00K |
| Net Income Ratio | -223.86% | -571.60% | -212.88% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29.08% | 30.32% | 23.73% | 19.38% | 8.77% | 1.90% | -12.15% | -22.87% | -26.20% | -41.36% | -17.44% | -63.99% | -79.53% | -61.59% | -192.33% | -419.54% | -377.27% | -18.52% | -29.60% | -38.39% | -11.45% | 2.80% |
| EPS | -0.28 | -1.10 | -1.05 | 0.10 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.09 | 0.51 | 0.55 | 0.20 | 0.25 | 0.25 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| EPS Diluted | -0.28 | -1.10 | -1.05 | 0.09 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.08 | 0.50 | 0.53 | 0.19 | 0.24 | 0.24 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| Weighted Avg Shares Out | 134.88M | 84.97M | 80.12M | 76.27M | 66.75M | 63.32M | 53.86M | 34.41M | 28.67M | 28.53M | 28.52M | 28.38M | 27.69M | 27.29M | 26.98M | 25.65M | 26.12M | 24.95M | 23.80M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
| Weighted Avg Shares Out (Dil) | 134.88M | 84.97M | 80.12M | 83.80M | 66.75M | 63.32M | 53.86M | 34.64M | 28.93M | 28.92M | 28.87M | 28.73M | 28.93M | 28.97M | 28.55M | 27.81M | 27.98M | 26.40M | 26.49M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
VERU DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) in the United States Southern District Court...
FRIDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Veru Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - February 1, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. ("Veru" or "the Company") (NASDAQ: VERU) for violations of §§10(b) and...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Veru Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 6, 2023 - (NASDAQ: VERU)
NEW YORK , Feb. 1, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Veru Inc.. Shareholders who purchased shares of VERU during the class period listed are encouraged to contact the firm regarding possible lead...
VERU INC. (NASDAQ: VERU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Veru Inc. (NASDAQ: VERU)
Did you lose money on investments in Veru? If so, please visit Veru Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Veru Inc. (VERU) Investors to Feb. 6th Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm's Attorneys
San Francisco, California--(Newsfile Corp. - January 31, 2023) - Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now.Class Period: May 11, 2022 - Nov. 9, 2022Lead Plaintiff Deadline: Feb. 6, 2023Visit: www.hbsslaw.com/investor-fraud/VERU Contact...
VERU Deadline Notice: ROSEN, Global Investor Counsel, Encourages Veru, Inc. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action - VERU
New York, New York--(Newsfile Corp. - January 31, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and November 9, 2022, both dates...
FRIDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Veru Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 31, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Veru Inc. ("Veru" or "the Company") (NASDAQ: VERU) for violations of §§10(b) and...
VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders
NEW YORK , Jan. 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Veru Inc. (NASDAQ: VERU) alleging that the Company violated federal securities laws. This lawsuit is...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Veru Investors of a Lead Plaintiff Deadline of February 6, 2023
NEW YORK , Jan. 30, 2023 /PRNewswire/ -- Attention Veru Inc. ("Veru") (NASDAQ: VERU) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all...
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
MIAMI, FL, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced it will host a conference call and audio...
Source: https://incomestatements.info
Category: Stock Reports